>>Signaling Pathways>> Others>>CS476 (NSC302998)

CS476 (NSC302998) (Synonyms: NSC302998)

Catalog No.GC32638

CS476(NSC302998)는 강력한 혈당강하제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

CS476 (NSC302998) Chemical Structure

Cas No.: 41177-35-9

Size 가격 재고 수량
1mg
US$809.00
재고 있음
5mg
US$1,609.00
재고 있음
10mg
US$2,794.00
재고 있음
20mg
US$4,890.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CS476 is a potent hypoglycaemic agent.

In normal fasting dogs, rabbits, rats and mice the maximal hypoglycaemia produced by intravenous administration of CS476 is comparable on a weight basis to that produced by Glibenclamide. Randomized Latin square experiments in dogs show that 0.03 mg/kg orally of CS476 and of Glibenclamide cause the same maximal decrease of blood glucose and that CS476 has the shorter duration of action. CS476 has no hypoglycaemic effect in totally pancreatectomized dogs nor in streptozotocin diabetic dogs and rats. The insulin releasing activity is studied in dogs after intravenous and oral administration of equipotent doses of CS476, Tolbutamide and Glibenclamide[1].

[1]. Jorgensen KD. The pharmacology of a new hypoglycaemic agent N-[4-(2-(2,3-dihydrobenzo(b)furan-m-carboxamido)-ethyl)-benzenesulphonyl]-N'-cyclohexylurea (NOVO CS 476). I. Pharmacological studies on the hypoglycaemic effect. Acta Pharmacol Toxicol (Copenh). 1977 Feb;40(2):216-26.

리뷰

Review for CS476 (NSC302998)

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CS476 (NSC302998)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.